Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Advancing the STATus of MPN pathogenesis.

Shah NP, Shannon K.

Blood. 2012 Apr 12;119(15):3374-6. doi: 10.1182/blood-2012-02-406611.

2.

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA.

Blood. 2012 Apr 12;119(15):3550-60. doi: 10.1182/blood-2011-12-397554. Epub 2012 Jan 10.

3.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.

PMID:
22051730
4.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
5.

[Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].

Funakoshi-Tago M.

Yakugaku Zasshi. 2011;131(8):1183-7. Review. Japanese.

6.

Critical requirement for Stat5 in a mouse model of polycythemia vera.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Apr 12;119(15):3539-49. doi: 10.1182/blood-2011-03-345215. Epub 2011 Dec 5.

7.

JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Scott LM, Rebel VI.

Am J Hematol. 2012 Nov;87(11):1028-36. doi: 10.1002/ajh.23243. Epub 2012 May 28. Review.

8.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60. Epub 2006 May 2.

9.

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.

Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.

Coll Antropol. 2012 Sep;36(3):859-65.

PMID:
23213945
10.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
11.

Imatinib effect on growth and signal transduction in polycythemia vera.

Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT.

Exp Hematol. 2007 Jun;35(6):931-8.

PMID:
17533047
12.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

13.

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, Vainchenker W, Villeval JL.

Blood. 2010 Aug 5;116(5):783-7. doi: 10.1182/blood-2009-12-257063. Epub 2010 May 14.

14.

Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.

Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, Handa H, Murakami H, Nojima Y, Tsukamoto N.

Intern Med. 2011;50(21):2557-61. Epub 2011 Nov 1.

15.

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.

Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.

16.

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.

Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I.

Leukemia. 2013 Nov;27(11):2187-95. doi: 10.1038/leu.2013.102. Epub 2013 Apr 5.

PMID:
23558526
17.
18.

JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.

Zhang S, Qiu H, Fischer BS, Li W, Duan L, Sun X, Xu W, Li J.

Leuk Lymphoma. 2008 Apr;49(4):696-9. doi: 10.1080/10428190701885537.

PMID:
18398736
19.

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, Villeval JL.

Blood. 2013 Aug 22;122(8):1464-77. doi: 10.1182/blood-2013-04-498956. Epub 2013 Jul 17.

20.

Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.

Kurume Med J. 2014;60(3-4):89-97. Epub 2014 May 26.

Supplemental Content

Support Center